Alligator Bioscience presents at the SITC 35th Annual Meeting
Three projects showcased – ATOR-1015, ALG.APV-527 and Neo-X-Prime – Lund, Sweden, November 9, 2020 – Alligator Bioscience (N ...
Alligator Bioscience presents the CD40 antibody mitazalimab at the World Immunotherapy Congress 2020
Strong benchmark to competitor CD40 antibodies Lund, Sweden, November 5, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announc ...
Predicted therapeutic range dose levels reached in ATOR-1017 Phase I
Lund, Sweden, October 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced additional positive interim safety data from ...
Alligator Bioscience focuses on ATOR-1017 and mitazalimab
Lund, Sweden, October 22, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the decision to focus its resources on the t ...
Alligator Bioscience appoints Gayle Mills as Chief Business Officer
Lund, Sweden, September 28, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today the appointment of Gayle Mills as Chief Bu ...
Alligator Bioscience launches a new immuno-oncology concept
Lund, Sweden, September 24, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company launches a new concept fo ...
Alligator Bioscience receives patent approval for the drug candidate ATOR-1015
Lund, Sweden, September 16, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the United States Patent and Trademar ...
Alligator Bioscience presents an update regarding the Phase I study with the drug candidate ATOR-1015
Lund, Sweden, September 9, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today updated timelines indicating 3-6 months del ...
Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study
Lund, Sweden, September 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today biomarker data from a recently performed cl ...